Intestinal bacteria and inflammatory bowel disease.

Area of Science:

• Gastroenterology and Microbiology
• Focuses on the complex interplay between the gut microbiome and inflammatory bowel disease (IBD).

Background:

• Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a significant health concern.
• While genetic, environmental, and lifestyle factors are implicated, the primary etiologic agents, particularly microorganisms, are not definitively identified.
• Existing research highlights the involvement of bacteria in IBD pathogenesis.

Purpose of the Study:

• To review the potential role of luminal and mucosal microbial communities in the etiology of IBD.
• To outline studies investigating various biotherapeutic interventions for IBD.

Main Methods:

• Literature review of studies on the gut microbiome in IBD.
• Analysis of research on biotherapeutic agents including antibiotics, probiotics, prebiotics, and synbiotics.
• Examination of animal studies and human data regarding microbial involvement.

Main Results:

• The precise causative microorganisms for IBD remain elusive despite numerous candidate identifications.
• Biotherapeutic strategies, including antibiotics, probiotics, prebiotics, and synbiotics, show potential in managing IBD.
• The composition of luminal and mucosal microbial communities is increasingly recognized as critical in IBD development.

Conclusions:

• The etiology of IBD is multifactorial, with the gut microbiome playing a crucial, yet not fully understood, role.
• Biotherapeutic approaches targeting the gut microbiota represent a promising avenue for IBD management and treatment.
• Further research is needed to elucidate the specific microbial agents and mechanisms driving IBD.